HTLV Como Fator De Risco E Gravidade Ao Covid-19 - Relato De Dois Casos

Carvalho, Luiz Guilherme; Rocha, Mtl; Chagas, V. M.; Junior, Vianna; Aroucha, A. Q. M. S.; Correia, M. C. B.; Costa, Manuela

doi:10.1016/j.htct.2020.10.906

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunology of the co-infection suggests an increased risk of COVID-19 disease severity due to dysregulated T-cell functioning and increased cytokine release in patients with HTLV-1/2 infection [ 11 ]. Isolated cases of the co-infection have been described in Brazil and Japan [ 12 , 16 , 17 ]. A case report from Japan described a severe case of COVID-19 in a 73-year-old patient who had not been previously diagnosed with HTLV-1; the patient died 3-months after symptom onset due to uncontrollable infections while on continuous ventilatory support [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between HTLV-1/2 infection and COVID-19 severity in a migrant Shipibo-Konibo population in Lima, Peru

Avila Dextre,

Morales Álvarez,

Aguirre Castañeda

et al. 2024

PLOS Glob Public Health

View full text Add to dashboard Cite

Objectives The migrant community of the Shipibo-Konibo indigenous people in Lima, Peru were extremely vulnerable during the COVID-19 pandemic. Additionally, infection with human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) is endemic in this population causing immunosuppression. The aim of the study was to describe the association between HTLV-1/2 infection and the clinical severity of COVID-19. Methods This was a cross-sectional descriptive study involving a survey of adult Shipibo-Konibo indigenous migrants residing in Cantagallo-Rímac who were identified as suspected or confirmed cases of COVID-19. Blood samples were collected for SARS-CoV-2 antibody and HTLV-1/2 ELISA testing. A confirmatory Western Blot test was performed for those with a positive ELISA test. Results A total of 182 individuals were surveyed and sampled. No significant association was found between HTLV-1/2 infection and the clinical severity of COVID-19. The prevalence of HTLV-1/2 was 8.8% (95%CI: 5.0–14.1) with Western Blot. Age was the only statistically significant risk factor for developing a more severe form of COVID-19 (OR: 1.03; 95%CI: 1.00–1.06; p = 0.032). Conclusions There was no association found between HTLV-1/2 infection and the clinical severity of COVID-19. The prevalence of HTLV-1/2 infection in the Shipibo-Konibo population is high and warrants continuous monitoring in the advent of other infectious disease outbreaks and the development of HTLV-associated comorbidities.

show abstract

Section: Discussionmentioning

confidence: 99%

“…On the other hand, another case has been reported in a patient with adult T-cell leukaemia who, despite presenting immunosuppression, did not develop severe pneumonia due to COVID-19 [ 17 ]. Furthermore, two patients with known HTLV-1/2 infection in Brazil also presented with mild COVID-19 severity [ 16 ]…”

Section: Discussionmentioning

confidence: 99%